EGFR

Epidermal growth factor receptor (EGFR; HER-1) is expressed in the whole epidermis of normal skin. Additionally, aberrant EGFR activity is linked to a wide range of solid tumors. Overexpression of EGFR, often combined with EGFR mutations that cause hyper-activity, are linked to rapid growth of tumor cells. As a result, EGFR and EGFR-signaling is an attractive target for more specific cancer therapies. Several anti-EGFR monoclonal antibodies have already been clinically approved. Additionally, much work on developing antibody drug conjugates and chemotherapeutic nanoparticles use EGFR as a target.

Imanis offers several EGFR-positive tumor cell line models. Natural EGFR expression in the parental cells has been confirmed by flow cytometry, and stable reporter expression in the engineered reporter cells facilitates in vivo and in vitro studies.

Cell lines endogenously expressing EGFR

Cell Line	Expression	EGFR surface profile in parental cells used to make Imanis cell lines
HT1080	Express EGFR
A549	Express EGFR
A375	Express EGFR
HCT116	Express EGFR
PC3	Express EGFR

Imanis also offers modified EGFR-expression cell lines, in which the cells have been engineered to change their natural EGFR expression levels.